TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE
Clinical safety rating: safe
CNS depressants may enhance sedative effects May cause marked drowsiness and impair mental and physical abilities.
Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, producing analgesia and antitussive effects. Triprolidine is a first-generation antihistamine blocking H1 receptors, reducing histamine effects. Pseudoephedrine is a sympathomimetic amine acting as a decongestant via alpha-adrenergic receptor agonism in respiratory tract mucosa.
| Metabolism | Codeine is primarily metabolized by CYP2D6 to morphine (active), CYP3A4 to norcodeine, and to a lesser extent by glucuronidation. Triprolidine is metabolized by hepatic enzymes. Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted unchanged in urine. |
| Excretion | Codeine: renal elimination of metabolites (primarily codeine-6-glucuronide, norcodeine, and morphine glucuronides); approximately 90% excreted renally, with about 10% as unchanged codeine. Triprolidine: renal elimination (80-90% as metabolites, <5% unchanged). Pseudoephedrine: renal elimination (70-90% unchanged, dependent on urine pH). |
| Half-life | Codeine: 2.5-3.5 hours; clinical context: short half-life necessitates frequent dosing. Triprolidine: 3-5 hours; clinical context: typical dosing every 4-6 hours. Pseudoephedrine: 5-8 hours (alkaline urine prolongs to ~10-13 hours); clinical context: extended-release formulations available. |
| Protein binding | Codeine: ~7-25% bound to albumin. Triprolidine: no specific data, likely low (<20%). Pseudoephedrine: negligible (<5%) binding to plasma proteins. |
| Volume of Distribution | Codeine: 3-6 L/kg. Triprolidine: approximately 2-4 L/kg. Pseudoephedrine: 2-3 L/kg. Clinical meaning: large Vd indicates extensive tissue distribution. |
| Bioavailability | Oral: Codeine ~53% (extensive first-pass metabolism). Triprolidine: not well established; estimated 70-80% (based on related alkylamines). Pseudoephedrine: ~100% (well absorbed, minimal first-pass metabolism). |
| Onset of Action | Oral: Codeine analgesia 30-60 minutes; Triprolidine antihistamine effect 1-2 hours; Pseudoephedrine decongestant effect 15-30 minutes. |
| Duration of Action | Codeine: 4-6 hours (analgesia). Triprolidine: 4-6 hours (antihistamine). Pseudoephedrine: 4-6 hours (immediate-release), up to 12 hours (extended-release). Clinical note: Combined formulation duration is limited by the shortest-acting component. |
| Molecular Weight | Codeine phosphate: 397.37 Da; Pseudoephedrine HCl: 201.69 Da; Triprolidine HCl: 302.34 Da |
| Action Class | Antihistamine, decongestant, opioid antitussive |
Oral: 1 tablet (triprolidine 2.5 mg, pseudoephedrine 60 mg, codeine 30 mg) every 4-6 hours as needed; maximum 4 tablets per day.
| Dosage form | SYRUP |
| Renal impairment | GFR 30-50 mL/min: Administer every 6 hours; GFR 10-29 mL/min: Administer every 8 hours; GFR <10 mL/min: Not recommended due to risk of codeine accumulation. |
| Liver impairment | Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose or extend interval (e.g., every 8 hours); Child-Pugh Class C: Contraindicated. |
| Pediatric use | Not recommended for children under 18 years due to risk of respiratory depression from codeine. For ages ≥18, use adult dosing. |
| Geriatric use | Initiate with half the adult dose (e.g., 1/2 tablet) every 6-8 hours; monitor for CNS depression, constipation, and urinary retention; avoid if possible in frail elderly. |
| 1st trimester | Avoid use during first trimester due to potential teratogenic effects; codeine crosses placenta and may cause fetal dependence. |
| 2nd trimester | Use only if clearly needed; risk of respiratory depression and withdrawal in neonate. |
| 3rd trimester | Avoid near term; may cause respiratory depression and withdrawal symptoms in newborn. |
Clinical note
CNS depressants may enhance sedative effects May cause marked drowsiness and impair mental and physical abilities.
| FDA category | Animal |
| Placental transfer | Codeine and pseudoephedrine readily cross the placenta; codeine undergoes placental transfer with fetal plasma concentrations similar to maternal. |
| Breastfeeding |
■ FDA Black Box Warning
Codeine is contraindicated for postoperative pain management in children following tonsillectomy and/or adenoidectomy due to risk of respiratory depression and death. Concomitant use of codeine with all CYP3A4 inducers or inhibitors, or with alcohol/central nervous system depressants may increase risk of adverse reactions.
| Common Effects | Sedation |
| Serious Effects | Respiratory depression (especially with codeine in children, CYP2D6 ultra-rapid metabolizers, and elderly), Cardiovascular events (hypertension, tachycardia, arrhythmias, myocardial ischemia) from pseudoephedrine, CNS depression (sedation, dizziness, confusion) from triprolidine and codeine, Serotonin syndrome when combined with other serotonergic drugs, Seizures, Urinary retention, Increased intraocular pressure (angle-closure glaucoma), Paralytic ileus, Hypersensitivity reactions (anaphylaxis, angioedema) |
Hypersensitivity to any componentAsthma or COPD with bronchospasmRespiratory depressionMAO inhibitor use within 14 daysSevere hypertension or coronary artery diseasePheochromocytomaNarrow-angle glaucomaUrinary retentionConcurrent use of other CNS depressantsBreastfeeding (especially in ultra-rapid metabolizers)
| Precautions |
Loading safety data…
| Codeine is excreted into breast milk; risk of infant respiratory depression and CNS depression. Use is generally contraindicated, especially in mothers who are ultra-rapid metabolizers of codeine. |
| Lactation Rating | L4 (Possibly Hazardous) / Avoid |
| Teratogenic Risk | FDA Pregnancy Category C for codeine; no controlled data for triprolidine/pseudoephedrine. First trimester: codeine associated with increased risk of congenital malformations (oral clefts, neural tube defects) in some studies; second/third trimester: prolonged use may cause neonatal respiratory depression, withdrawal syndrome (irritability, hypertonia, tremors) and increased risk of preterm birth. Triprolidine/pseudoephedrine: limited data, but pseudoephedrine implicated in gastroschisis and hemifacial microsomia with first-trimester exposure. |
| Fetal Monitoring | Monitor maternal respiratory rate, sedation level, and blood pressure. Fetal monitoring for growth restriction and preterm labor with prolonged use. Neonatal monitoring for withdrawal symptoms (Finnegan scoring) and respiratory depression if used near term. |
| Fertility Effects | No definitive human data. Codeine may alter hypothalamic-pituitary-gonadal axis, potentially affecting ovulation and libido. Pseudoephedrine can cause vasoconstriction of uterine vessels, theoretically impairing implantation; no established effect on fertility. |
| Serious, life-threatening respiratory depression in children; risk of addiction, abuse, and misuse; ultra-rapid metabolizers of CYP2D6 may convert codeine to morphine more rapidly; risk of medication errors; concomitant use with sedatives, hypnotics, or alcohol increases CNS depression; avoid in patients with severe hypertension or coronary artery disease; use caution in hyperthyroidism, diabetes, prostatic hypertrophy, increased intraocular pressure, or seizure disorders. |
| Food/Dietary | Avoid grapefruit juice as it may alter codeine metabolism. Take with food if GI upset occurs. Avoid high-tyramine foods (aged cheese, cured meats) with pseudephedrine due to risk of hypertensive crisis. |
| Clinical Pearls | Codeine is a prodrug converted to morphine via CYP2D6; efficacy and toxicity vary with CYP2D6 metabolizer status. Avoid in children <12 years due to risk of respiratory depression (FDA black box warning). Pseudephedrine can cause hypertensive crisis in patients with severe hypertension or coronary artery disease. Triprolidine adds anticholinergic effects; use cautiously in elderly, glaucoma, or urinary retention. |
| Patient Advice | Do not exceed recommended dose; may cause sedation/drowsiness. · Avoid alcohol and other CNS depressants. · If pregnant or breastfeeding, consult provider before use. · May cause dizziness; avoid driving until response known. · Report severe constipation, difficulty urinating, or slow/shallow breathing. · Can be habit-forming; use only as prescribed. · Discontinue and seek help if allergic reaction (rash, swelling, trouble breathing). |